Literature DB >> 27834617

A Multi-Center Review of Care Patterns and Outcomes in Necrotizing Soft Tissue Infections.

Iris Faraklas1, Derek Yang2, Michael Eggerstedt3, Yan Zhai1, Patrick Liebel1, Gareth Graves1, Sharmila Dissanaike2, Michael Mosier3, Amalia Cochran1.   

Abstract

BACKGROUND: Surgical debridement and broad-spectrum empiric antibiotics are first-line therapy for necrotizing soft tissue infections (NSTI). The objective of this multi-center retrospective review was to evaluate antimicrobial agent initiation and duration and compare outcomes in the treatment of patients with NSTI. PATIENTS AND METHODS: This review included adults with NSTI, as indicated by International Classification of Diseases, 9th Edition, Clinical Modification codes 728.86, 608.33, or 040.0, who were admitted to three academic institutions between 1/1/09 and 5/15/14. Demographics, antibiotic practices, operative management, and clinical outcomes were compared.
RESULTS: A total of 341 patients were identified at the three centers. Subjects were comparable in age (median 53 years, p = 0.14), gender (67% male, p = 0.57) and body mass index (median 31.9 (p = 0.31) between sites. No significant difference was found in time from admission to start of empiric antibiotic therapy between the three centers (median 1 d for each, p = 0.70), but duration of antibiotic therapy was significantly different (Site A = 16 d, Site B = 12 d, Site C = 9 d, medians, p < 0.001). Although total number of operations differed between sites (median of two at Sites A and B, three at Site C, p = 0.001), sites consistently operated on the day of patient arrival to their facility, and the number of debridements did not differ (median of two for all sites, p = 0.10). Mortality rate (Site A = 22%, Site B = 18%, and Site C = 9%, p = 0.02) and length of stay for survivors (Site A = 29 d, Site B = 16 d, Site C = 19 d, medians, p = 0.001) was significantly different among centers.
CONCLUSIONS: Variation in antibiotic duration between centers with expertise in the care of NSTI illustrates how little is known about best care practices for patients with NSTI. Future studies should emphasize development of evidence-based practices for NSTI management to further improve the outcomes of this complex group of patients.

Entities:  

Keywords:  antibiotic therapy; necrotizing fasciitis; necrotizing soft tissue infection; outcomes

Mesh:

Substances:

Year:  2016        PMID: 27834617      PMCID: PMC5124740          DOI: 10.1089/sur.2015.238

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  17 in total

1.  The microbiology of necrotizing soft tissue infections.

Authors:  D Elliott; J A Kufera; R A Myers
Journal:  Am J Surg       Date:  2000-05       Impact factor: 2.565

2.  Practice guidelines for the diagnosis and management of skin and soft-tissue infections.

Authors:  Dennis L Stevens; Alan L Bisno; Henry F Chambers; E Dale Everett; Patchen Dellinger; Ellie J C Goldstein; Sherwood L Gorbach; Jan V Hirschmann; Edward L Kaplan; Jose G Montoya; James C Wade
Journal:  Clin Infect Dis       Date:  2005-10-14       Impact factor: 9.079

3.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

4.  Trends in 393 necrotizing acute soft tissue infection patients 2000-2008.

Authors:  Nicole P Bernal; Barbara A Latenser; Janelle M Born; Junlin Liao
Journal:  Burns       Date:  2011-10-24       Impact factor: 2.744

5.  The care of necrotizing soft-tissue infections: patterns of definitive intervention at a large referral center.

Authors:  Michael Eggerstedt; Richard L Gamelli; Michael J Mosier
Journal:  J Burn Care Res       Date:  2015 Jan-Feb       Impact factor: 1.845

6.  Outcomes from treatment of necrotizing soft-tissue infections: results from the National Surgical Quality Improvement Program database.

Authors:  Megan K Mills; Iris Faraklas; Cherisse Davis; Gregory J Stoddard; Jeffrey Saffle
Journal:  Am J Surg       Date:  2010-12       Impact factor: 2.565

7.  Local variations in the epidemiology, microbiology, and outcome of necrotizing soft-tissue infections: a multicenter study.

Authors:  Lillian S Kao; Debbie F Lew; Samer N Arab; S Rob Todd; Samir S Awad; Matthew M Carrick; Michael G Corneille; Kevin P Lally
Journal:  Am J Surg       Date:  2011-05-04       Impact factor: 2.565

8.  Transfer status: a risk factor for mortality in patients with necrotizing fasciitis.

Authors:  Daniel N Holena; Angela M Mills; Brendan G Carr; Chris Wirtalla; Babak Sarani; Patrick K Kim; Benjamin M Braslow; Rachel R Kelz
Journal:  Surgery       Date:  2011-07-23       Impact factor: 3.982

9.  A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial.

Authors:  Eileen M Bulger; Ronald V Maier; Jason Sperry; Manjari Joshi; Sharon Henry; Frederick A Moore; Lyle L Moldawer; Demetrios Demetriades; Peep Talving; Martin Schreiber; Bruce Ham; Mitchell Cohen; Steven Opal; Irit Segalovich; Greg Maislin; Raymond Kaempfer; Anat Shirvan
Journal:  JAMA Surg       Date:  2014-06       Impact factor: 14.766

10.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

Authors:  Jean Chastre; Michel Wolff; Jean-Yves Fagon; Sylvie Chevret; Franck Thomas; Delphine Wermert; Eva Clementi; Jesus Gonzalez; Dominique Jusserand; Pierre Asfar; Dominique Perrin; Fabienne Fieux; Sylvie Aubas
Journal:  JAMA       Date:  2003-11-19       Impact factor: 56.272

View more
  9 in total

Review 1.  Evaluation and Management of Necrotizing Soft Tissue Infections.

Authors:  Stephanie L Bonne; Sameer S Kadri
Journal:  Infect Dis Clin North Am       Date:  2017-09       Impact factor: 5.982

2.  Necrotizing Soft Tissue Infections at a Tertiary Referral Hospital in Rwanda: Epidemiology and Risk Factors for Mortality.

Authors:  Christophe Mpirimbanyi; Jennifer Rickard; Charles Furaha; Faustin Ntirenganya
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

Review 3.  Necrotizing Soft Tissue Infections of the Perineum.

Authors:  Bryan P Kline; Nimalan A Jeganathan
Journal:  Clin Colon Rectal Surg       Date:  2022-02-09

4.  Survival and Health-Related Quality of Life after Hospitalization for Necrotizing Soft Tissue Infections of the Upper Extremity: A Long-Term Outcome Study.

Authors:  Femke Nawijn; Svenna H W L Verhiel; Juliette Nierich; Kyle R Eberlin; Falco Hietbrink; Neal C Chen
Journal:  J Hand Microsurg       Date:  2020-05-06

5.  Frozen sections are unreliable for the diagnosis of necrotizing soft tissue infections.

Authors:  Isaac H Solomon; Rene Borscheid; Alvaro C Laga; Reza Askari; Scott R Granter
Journal:  Mod Pathol       Date:  2017-12-15       Impact factor: 7.842

6.  Severe bacterial skin infections.

Authors:  Sílvio Alencar Marques; Luciana Patrícia Fernandes Abbade
Journal:  An Bras Dermatol       Date:  2020-05-16       Impact factor: 1.896

7.  Exhaustion of the immune system by Group A Streptococcus necrotizing fasciitis: the occurrence of late secondary infections in a retrospective study.

Authors:  Femke Nawijn; Emma C E Wassenaar; Diederik P J Smeeing; Bart J M Vlaminckx; Jan Siert K Reinders; Jan Wille; Luke P H Leenen; Falco Hietbrink
Journal:  Trauma Surg Acute Care Open       Date:  2019-02-06

8.  Impact of a multidisciplinary care bundle for necrotizing skin and soft tissue infections: a retrospective cohort study.

Authors:  Tomas Urbina; Camille Hua; Emilie Sbidian; Romain Bosc; Françoise Tomberli; Raphael Lepeule; Jean-Winoc Decousser; Armand Mekontso Dessap; Olivier Chosidow; Nicolas de Prost
Journal:  Ann Intensive Care       Date:  2019-10-24       Impact factor: 6.925

9.  Necrotizing fasciitis secondary to lake water inoculation with Aeromonas sobria: A case report.

Authors:  Lauren E Hutchinson; Jacob D Franke; Brian A Mailey
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.